BLOSSOMHILL THERAPEUTICS
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.
BLOSSOMHILL THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2020-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.bhtherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
71 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Cytocom
Cytocom is a biopharmaceutical company focused on analogs that treat multiple diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Interius BioTherapeutics
Interius BioTherapeutics is a biopharmaceutical company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.
KeChow Pharma
KeChow Pharma, Inc. is a biopharmaceutical company focused on novel drug discovery.
Monopar
Monopar Therapeutics is an emerging biopharmaceutical company focused on developing orphan oncology compounds.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Wren Therapeutics
Wren Therapeutics is a biopharmaceutical company based, focused on drug discovery and development for protein misfolding diseases.
XinThera
XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.
Current Advisors List
Current Employees Featured
Founder
Investors List
Hercules Bioventure Partners
Hercules Bioventure Partners investment in Series A - BlossomHill Therapeutics
OrbiMed
OrbiMed investment in Series A - BlossomHill Therapeutics
Vivo Capital
Vivo Capital investment in Series A - BlossomHill Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series A - BlossomHill Therapeutics
Official Site Inspections
http://www.bhtherapeutics.com
Unable to get host informations!!!
More informations about "BlossomHill Therapeutics"
About | BlossomHill Therapeutics
May 29, 2024 Dr. J. Jean Cui has a prolific track record as a cancer drug designer and developer. Three molecules designed by Dr. Cui have become โฆSee details»
BlossomHill Therapeutics - Crunchbase Company โฆ
Contact Email [email protected] BlossomHill Therapeutics, Inc. is a โฆSee details»
BlossomHill Therapeutics, Inc.โs Post - LinkedIn
#ICYMI: Our President and CEO, Dr. J. Jean Cui, was recently elected to the National Academy of Engineering (NAE) for her innovation of new medicines to fight cancers and address urgent โฆSee details»
BlossomHill Therapeutics - VentureRadar
MtoZ Biolabs USA Privately Held MtoZ Biolabs is an international contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical โฆSee details»
Blossomhill Therapeutics, Inc. - Drug pipelines, Patents, Clinical ...
BH-30643 is a macrocyclic, mutant selective OMNI-EGFRโข inhibitor with sub-nanomolar potency against classical and atypical EGFR mutations that is maintained even in the presence of โฆSee details»
Blossomhill Therapeutics, Inc. (Blossomhill Therapeutics, Inc.) - ่ฏ โฆ
May 7, 2025 Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a strong syndicate of leading investors, including Cormorant Asset Management, OrbiMed, โฆSee details»
BlossomHill Therapeutics, Inc. | The Work Index by Flexa
BlossomHill Therapeutics emphasizes a culture that values human intelligence, creative thinking, and a track record of drug design expertise. They believe in a diverse team with a science โฆSee details»
Company Information - RocketReach
BlossomHill Therapeutics, Inc. employs 44 employees. The BlossomHill Therapeutics, Inc. management team includes J Cui (Scientific Founder, President and CEO), Vince Liptak โฆSee details»
Blossomhill Therapeutics - Overview, News & Similar ... - ZoomInfo
Blossomhill Therapeutics contact info: Phone number: (858) 732-3880 Website: www.bhtherapeutics.com What does Blossomhill Therapeutics do? Blossomhill Therapeutics โฆSee details»
Home | BlossomHill Therapeutics
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you โฆSee details»
BlossomHill Therapeutics Closes $71M Series A Financing
SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a biopharmaceutical company focusing on oncology and autoimmune disorders, announced โฆSee details»
BlossomHill Therapeutics
BlossomHill Therapeutics is developing small molecule therapeutics for unmet medical needs in oncology and autoimmune diseases. Founded by renowned drug design and development โฆSee details»
Careers | BlossomHill Therapeutics
We are a science-forward organization led by our luminary, Dr. Jean Cui, and we welcome all to traverse mountains, ridges, rivers and streams to BlossomHill and solve treatment resistance. โฆSee details»
Blossom Therapeutics (Blossom Therapeutics) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธด โฆ
May 7, 2025 Headquartered in San Diego, California, BlossomHill Therapeutics is supported by a strong syndicate of leading investors, including Cormorant Asset Management, OrbiMed, โฆSee details»
Science | BlossomHill Therapeutics
Despite significant advances in cancer therapy and precision medicine, cures remain elusive due to cancerโs remarkable ability to develop tolerance and resistance to treatments, one of the โฆSee details»
BHB Therapeutics - VentureRadar
BHB Therapeutics is based on research conducted in the labs of Eric Verdin, MD and John Newman, MD, PhD. The work centers on the emerging signalling functions of a metabolite โฆSee details»
BH-30236 - Drug Targets, Indications, Patents - Synapse
May 7, 2025 BH-30236: a CLK1 inhibitors, CLK2 inhibitors, CLK4 inhibitors Drug, Initially developed by Blossomhill Therapeutics, Inc., Now, its global highest R&D status is Phase 1, โฆSee details»
BIO Announces Dedicated Focus on Human Health and โฆ
1 day ago Washington, DC, May 28, 2025 โ The Biotechnology Innovation Organization (BIO) today announced plans to dedicate its focus entirely to human health and to transition the work โฆSee details»
Pipeline | BlossomHill Therapeutics
We are evaluating a potentially better way to treat EGFR-positive NSCLC. BH-30643 is a mutant-selective OMNI-EGFR โข inhibitor with an aim to provide greater benefit to patients by:. Super โฆSee details»
Terms of Service | BlossomHill Therapeutics
You have the right to opt-out and not be bound by the arbitration provisions set forth in these Terms by sending written notice of your decision to opt-out to [email protected]. The โฆSee details»